The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

Rathmell: We need a “March Madness” for cancer research

“Cancer is a tremendously challenging tournament, but we are in it to win”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The views expressed here are those of Kimryn Rathmell alone.

Dear Colleagues,

Although this column is running in The Cancer Letter, where we turn for timely insights and information relevant to the cancer community, I suspect that a lot of our readers are watching college basketball this week. 

After all, March Madness, or the NCAA college basketball tournament to determine the national championship, has become an annual event at colleges, living rooms, and sports bars around the U.S. Even those who don’t follow the sport during the season track their favorite school—their alma mater, or a school with their favorite stellar cancer center —to see how far they go. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
W. Kimryn Rathmell, MD, PhD, MMHC
Former director, National Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
By Paul Goldberg and Claire Marie Porter
Clinical Roundup

Trodelvy + Keytruda show potential as new standard of care in first-line PD-L1+ metastatic TNBC, phase III trial finds

Patients saw a 35% reduced risk of disease progression or death for Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) (n=221) versus standard of care Keytruda plus chemotherapy (n=222), according to the positive phase III ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy plus Keytruda in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer. 
Byline
W. Kimryn Rathmell, MD, PhD, MMHC
Former director, National Cancer Institute
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account